Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system
Doctors tell MM&M that prescription weight-loss medications are just one component of an obesity treatment regimen.
The drugmaker released interim clinical trial information in an SEC filing that the FDA wanted kept quiet until the trial was completed.
Category news shows that marketing to the obese may mean marketing to related conditions.
Takeda and Orexigen's prescription weight-loss drug Contrave has hit the market with a wraparound patient support system.
Takeda's Director of Obesity Marketing Katie Andino told MM&M in a phone interview that the drugmaker will be taking a unique approach to woo patients, physicians and payers.
The latest data shows an overall widening of the US.
Baylor College of Medicine researchers have found that an estrogen replacement suppressed binge-eating behavior among lab mice.
J&J subsidiary Janssen has abandoned its patent lawsuit over the anti-seizure medication topiramate, which is part of Vivus's prescription weight-loss drug Qsymia.
An experimental Gelesis weight-loss drug seeks the middle ground between surgery and appetite suppressants.
Lawmakers criticized Columbia University chairman and professor of surgery Dr. Mehmet Oz for calling weight-loss supplements miracles on his TV program, despite lacking scientific proof to support those claims.
The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.
The regulator wants more time to discuss post-marketing requirements.
Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.
Eisai announced it was adding sales reps to promote its drug Belviq, while Vivus, maker of Qsymia, fights off a generic marketing application by Actavis.
Arena and Eisai are testing Belviq with appetite suppressant phentermine.
A national survey indicates that obesity rates for children ages 2 to 5 has fallen since the early 2000s, yet overall numbers remain largely unchanged and high.
Analyst Thomas Wei reviews the prescription slimming category and sees two different realities for Vivus and Arena.
The drugmaker says interim trial data meets FDA review requirements and is hoping for June 2014 approval.
The marketing push follows the September launch of a patient support program and the announcement it was doubling its sales force.
A Credit Suisse analyst notes that the company will need to make a significant impact to meet even lowered expectations. A possible fix: more sales reps behind Belviq.
Australia's price watchdogs are assessing the value of BMS cancer drug Yervoy; why a Phase II weight drug from Zafgen could open up the category; GSK halts a Crohn's trial; and Shire extends Santaris rare-disease collaboration
Eisai lobbies to push back Belviq's patent clock; a case against Paula Deen is dismissed; Merck and Avanir team up to promote Januvia; and another healthcare-reform measure is pushed back
GSK says change is afoot in China; Vivus fight reportedly results in a new CEO; Biogen Idec enters a collaboration in Edinburgh; Astellas wins and FDA approval; Myriad's patent fight continues
Analysts write expanded Qsymia distribution will do little to boost sales if payers are not on board.
When it comes to OTC weight-loss products, deceptive advertising produces diminishing returns, a study has found.
The drug maker is promoting the no-fee, all-access app to healthcare professionals as part of its Qsymia pitch.
Orexigen slashed its clinical trial recruitment period by 14 months using marketing tactics associated with retail.
The category that saw its first FDA-approved drug in 13 years is still waiting to take off.
PR firm Burson-Marsteller launched a new healthcare subsidiary, Orexigen's net loss widened in Q2, and Corcept closed out its first full quarter with orphan treatment Korlym.
- Top 25 rare disease brands, by sales
- Five things for pharma marketers to know: Monday, February 13, 2016
- Five things for pharma marketers to know: Thursday, February 16, 2017
- Orphan drugs face criticism on prices — and from patients
- Five things for pharma marketers to know: Wednesday, February 15, 2017